Alpha-1 Antitrypsin Deficiency and Pregnancy

Alpha-1 Antitrypsin Deficiency (A1AD) is a hereditary condition characterized by low levels of circulating alpha-antitrypsin (AAT) in plasma. It is the best understood genetic risk factor for the development of chronic obstructive pulmonary disease (COPD). The diagnosis of A1AD is under-recognized....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Chronic obstructive pulmonary disease 2020-05, Vol.17 (3), p.326-332
Hauptverfasser: Gaeckle, Nate T., Stephenson, Laurel, Reilkoff, Ronald A.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 332
container_issue 3
container_start_page 326
container_title Chronic obstructive pulmonary disease
container_volume 17
creator Gaeckle, Nate T.
Stephenson, Laurel
Reilkoff, Ronald A.
description Alpha-1 Antitrypsin Deficiency (A1AD) is a hereditary condition characterized by low levels of circulating alpha-antitrypsin (AAT) in plasma. It is the best understood genetic risk factor for the development of chronic obstructive pulmonary disease (COPD). The diagnosis of A1AD is under-recognized. While there is a significant heterogeneity in disease presentation in relation to the severity of symptoms and prognosis, it is not uncommon for young individuals, including pregnant women to already have moderate to advanced lung disease at the time of diagnosis. Reductions in AAT levels may have unique implications for a gravid patient beyond that of lung disease. Care of the pregnant A1AD patient with chronic lung disease follows the principles of care for the management of airways disease in general with control of symptoms and reduction in exacerbation risk the main tenets of treatment. The effect of A1AD and augmentation in pregnancy has not been studied and thus care is reliant on expert opinion and clinical experience. Providers caring for pregnant patients with A1AD should consider referral to health care systems and providers with specific expertise in A1AD. Ultimately the decision is left to the individual patient and their physician to weigh the risk benefit of cessation or continuation of therapies. In this review, we present the perinatal course of a woman with A1AD and review the available literature pertaining to AAT and pregnancy and discuss the clinical implications.
doi_str_mv 10.1080/15412555.2020.1754778
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_2392457183</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2392457183</sourcerecordid><originalsourceid>FETCH-LOGICAL-c366t-71094433f62f67969deb0c243cf42e6f631477a07af6f79e1aab180424b8cdb53</originalsourceid><addsrcrecordid>eNp9kMlOwzAURS0EoqXwCaAsWZDi2cmOqoxSJVjA2nIcG4wSJ9ipUP4eVx2WrN6ge-97OgBcIjhHsIC3iFGEGWNzDHFaCUaFKI7AdLPPMePk-NAzNgFnMX5DiBkl7BRMCCYpg8EpuFk0_ZfKUbbwgxvC2Efns3tjnXbG6zFTvs7egvn0Kk3n4MSqJpqLXZ2Bj8eH9-Vzvnp9elkuVrkmnA-5QLCklBDLseWi5GVtKqgxJdpSbLjlBKVnFRTKcitKg5SqUAEpplWh64qRGbje5vah-1mbOMjWRW2aRnnTraPEpMSUCVSQJGVbqQ5djMFY2QfXqjBKBOUGlNyDkhtQcgcq-a52J9ZVa-qDa08mCe62AudtF1r124WmloMamy7YkGi4KMn_N_4AbWJ0-w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2392457183</pqid></control><display><type>article</type><title>Alpha-1 Antitrypsin Deficiency and Pregnancy</title><source>EZB-FREE-00999 freely available EZB journals</source><creator>Gaeckle, Nate T. ; Stephenson, Laurel ; Reilkoff, Ronald A.</creator><creatorcontrib>Gaeckle, Nate T. ; Stephenson, Laurel ; Reilkoff, Ronald A.</creatorcontrib><description>Alpha-1 Antitrypsin Deficiency (A1AD) is a hereditary condition characterized by low levels of circulating alpha-antitrypsin (AAT) in plasma. It is the best understood genetic risk factor for the development of chronic obstructive pulmonary disease (COPD). The diagnosis of A1AD is under-recognized. While there is a significant heterogeneity in disease presentation in relation to the severity of symptoms and prognosis, it is not uncommon for young individuals, including pregnant women to already have moderate to advanced lung disease at the time of diagnosis. Reductions in AAT levels may have unique implications for a gravid patient beyond that of lung disease. Care of the pregnant A1AD patient with chronic lung disease follows the principles of care for the management of airways disease in general with control of symptoms and reduction in exacerbation risk the main tenets of treatment. The effect of A1AD and augmentation in pregnancy has not been studied and thus care is reliant on expert opinion and clinical experience. Providers caring for pregnant patients with A1AD should consider referral to health care systems and providers with specific expertise in A1AD. Ultimately the decision is left to the individual patient and their physician to weigh the risk benefit of cessation or continuation of therapies. In this review, we present the perinatal course of a woman with A1AD and review the available literature pertaining to AAT and pregnancy and discuss the clinical implications.</description><identifier>ISSN: 1541-2555</identifier><identifier>EISSN: 1541-2563</identifier><identifier>DOI: 10.1080/15412555.2020.1754778</identifier><identifier>PMID: 32308050</identifier><language>eng</language><publisher>England: Taylor &amp; Francis</publisher><subject>Alpha-1 antitrypsin ; alpha-1 antitrypsin deficiency ; asthma ; COPD ; pregnancy</subject><ispartof>Chronic obstructive pulmonary disease, 2020-05, Vol.17 (3), p.326-332</ispartof><rights>2020 Taylor &amp; Francis Group, LLC 2020</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c366t-71094433f62f67969deb0c243cf42e6f631477a07af6f79e1aab180424b8cdb53</citedby><cites>FETCH-LOGICAL-c366t-71094433f62f67969deb0c243cf42e6f631477a07af6f79e1aab180424b8cdb53</cites><orcidid>0000-0003-1200-6242</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32308050$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gaeckle, Nate T.</creatorcontrib><creatorcontrib>Stephenson, Laurel</creatorcontrib><creatorcontrib>Reilkoff, Ronald A.</creatorcontrib><title>Alpha-1 Antitrypsin Deficiency and Pregnancy</title><title>Chronic obstructive pulmonary disease</title><addtitle>COPD</addtitle><description>Alpha-1 Antitrypsin Deficiency (A1AD) is a hereditary condition characterized by low levels of circulating alpha-antitrypsin (AAT) in plasma. It is the best understood genetic risk factor for the development of chronic obstructive pulmonary disease (COPD). The diagnosis of A1AD is under-recognized. While there is a significant heterogeneity in disease presentation in relation to the severity of symptoms and prognosis, it is not uncommon for young individuals, including pregnant women to already have moderate to advanced lung disease at the time of diagnosis. Reductions in AAT levels may have unique implications for a gravid patient beyond that of lung disease. Care of the pregnant A1AD patient with chronic lung disease follows the principles of care for the management of airways disease in general with control of symptoms and reduction in exacerbation risk the main tenets of treatment. The effect of A1AD and augmentation in pregnancy has not been studied and thus care is reliant on expert opinion and clinical experience. Providers caring for pregnant patients with A1AD should consider referral to health care systems and providers with specific expertise in A1AD. Ultimately the decision is left to the individual patient and their physician to weigh the risk benefit of cessation or continuation of therapies. In this review, we present the perinatal course of a woman with A1AD and review the available literature pertaining to AAT and pregnancy and discuss the clinical implications.</description><subject>Alpha-1 antitrypsin</subject><subject>alpha-1 antitrypsin deficiency</subject><subject>asthma</subject><subject>COPD</subject><subject>pregnancy</subject><issn>1541-2555</issn><issn>1541-2563</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kMlOwzAURS0EoqXwCaAsWZDi2cmOqoxSJVjA2nIcG4wSJ9ipUP4eVx2WrN6ge-97OgBcIjhHsIC3iFGEGWNzDHFaCUaFKI7AdLPPMePk-NAzNgFnMX5DiBkl7BRMCCYpg8EpuFk0_ZfKUbbwgxvC2Efns3tjnXbG6zFTvs7egvn0Kk3n4MSqJpqLXZ2Bj8eH9-Vzvnp9elkuVrkmnA-5QLCklBDLseWi5GVtKqgxJdpSbLjlBKVnFRTKcitKg5SqUAEpplWh64qRGbje5vah-1mbOMjWRW2aRnnTraPEpMSUCVSQJGVbqQ5djMFY2QfXqjBKBOUGlNyDkhtQcgcq-a52J9ZVa-qDa08mCe62AudtF1r124WmloMamy7YkGi4KMn_N_4AbWJ0-w</recordid><startdate>20200503</startdate><enddate>20200503</enddate><creator>Gaeckle, Nate T.</creator><creator>Stephenson, Laurel</creator><creator>Reilkoff, Ronald A.</creator><general>Taylor &amp; Francis</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-1200-6242</orcidid></search><sort><creationdate>20200503</creationdate><title>Alpha-1 Antitrypsin Deficiency and Pregnancy</title><author>Gaeckle, Nate T. ; Stephenson, Laurel ; Reilkoff, Ronald A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c366t-71094433f62f67969deb0c243cf42e6f631477a07af6f79e1aab180424b8cdb53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Alpha-1 antitrypsin</topic><topic>alpha-1 antitrypsin deficiency</topic><topic>asthma</topic><topic>COPD</topic><topic>pregnancy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gaeckle, Nate T.</creatorcontrib><creatorcontrib>Stephenson, Laurel</creatorcontrib><creatorcontrib>Reilkoff, Ronald A.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Chronic obstructive pulmonary disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gaeckle, Nate T.</au><au>Stephenson, Laurel</au><au>Reilkoff, Ronald A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Alpha-1 Antitrypsin Deficiency and Pregnancy</atitle><jtitle>Chronic obstructive pulmonary disease</jtitle><addtitle>COPD</addtitle><date>2020-05-03</date><risdate>2020</risdate><volume>17</volume><issue>3</issue><spage>326</spage><epage>332</epage><pages>326-332</pages><issn>1541-2555</issn><eissn>1541-2563</eissn><abstract>Alpha-1 Antitrypsin Deficiency (A1AD) is a hereditary condition characterized by low levels of circulating alpha-antitrypsin (AAT) in plasma. It is the best understood genetic risk factor for the development of chronic obstructive pulmonary disease (COPD). The diagnosis of A1AD is under-recognized. While there is a significant heterogeneity in disease presentation in relation to the severity of symptoms and prognosis, it is not uncommon for young individuals, including pregnant women to already have moderate to advanced lung disease at the time of diagnosis. Reductions in AAT levels may have unique implications for a gravid patient beyond that of lung disease. Care of the pregnant A1AD patient with chronic lung disease follows the principles of care for the management of airways disease in general with control of symptoms and reduction in exacerbation risk the main tenets of treatment. The effect of A1AD and augmentation in pregnancy has not been studied and thus care is reliant on expert opinion and clinical experience. Providers caring for pregnant patients with A1AD should consider referral to health care systems and providers with specific expertise in A1AD. Ultimately the decision is left to the individual patient and their physician to weigh the risk benefit of cessation or continuation of therapies. In this review, we present the perinatal course of a woman with A1AD and review the available literature pertaining to AAT and pregnancy and discuss the clinical implications.</abstract><cop>England</cop><pub>Taylor &amp; Francis</pub><pmid>32308050</pmid><doi>10.1080/15412555.2020.1754778</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0003-1200-6242</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1541-2555
ispartof Chronic obstructive pulmonary disease, 2020-05, Vol.17 (3), p.326-332
issn 1541-2555
1541-2563
language eng
recordid cdi_proquest_miscellaneous_2392457183
source EZB-FREE-00999 freely available EZB journals
subjects Alpha-1 antitrypsin
alpha-1 antitrypsin deficiency
asthma
COPD
pregnancy
title Alpha-1 Antitrypsin Deficiency and Pregnancy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T04%3A12%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Alpha-1%20Antitrypsin%20Deficiency%20and%20Pregnancy&rft.jtitle=Chronic%20obstructive%20pulmonary%20disease&rft.au=Gaeckle,%20Nate%20T.&rft.date=2020-05-03&rft.volume=17&rft.issue=3&rft.spage=326&rft.epage=332&rft.pages=326-332&rft.issn=1541-2555&rft.eissn=1541-2563&rft_id=info:doi/10.1080/15412555.2020.1754778&rft_dat=%3Cproquest_pubme%3E2392457183%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2392457183&rft_id=info:pmid/32308050&rfr_iscdi=true